Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpFN_1B-06-PL + ALFQ
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SpFN_1B-06-PL + ALFQ is a recombinant protein-based vaccine candidate for the prevention of COVID-19. It consists of a self-assembling spike ferritin nanoparticle (SpFN), which displays the prefusion-stabilized SARS-CoV‑2 spike protein on a ferritin core, co-formulated with Army Liposomal Formulation QS21 (ALFQ) as an adjuvant. The vaccine is designed to elicit robust neutralizing antibody responses and broad protection against SARS-CoV‑2 and related coronaviruses by presenting multiple copies of the spike antigen in a highly immunogenic nanoparticle format. The addition of the liposomal adjuvant ALFQ enhances immune response magnitude and durability[3][4][5]. Developed primarily by military research institutions, it has been evaluated in phase 1 clinical trials for safety and immunogenicity in healthy adults[2][5].
- Other names
- SARS-CoV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ AdjuvantSpike-ferritin nanoparticle vaccine with Army Liposomal Formulation QS21 adjuvant
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SpFN_1B-06-PL + ALFQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpFN_1B-06-PL + ALFQ.